



PRESS RELEASE

CLONIT ACQUIRES 100% OF DIA.PRO

Clonit continues its growth path initiated in 2022 with the support of the Equita Smart Capital – ELTIF fund, aiming to create a leading center of excellence in molecular and immunological diagnostics. The Group is doubling its size, reaching a turnover of over €15 million, and strengthening its international presence.

Milan, 1 December 2025 – Clonit, a leading Italian company in the development of molecular tests for infectious and genetic diseases, backed by the private equity fund Equita Smart Capital ELTIF, managed by Equita Capital SGR, announces the acquisition of 100% of Dia.Pro – Diagnostic Bioprobes from its founding shareholders.

The acquisition marks a further step in the growth path undertaken by Clonit together with Equita, aimed at creating a leading group in the diagnostics sector.

With this transaction, **Clonit** consolidates its position in specific high-growth market niches, further expanding its portfolio of products and solutions as well as its technical-scientific expertise. Dia.Pro's product range will complement Clonit's already extensive offering, enabling—especially in infectious disease diagnostics—a complete assessment of infections from antigen to antibody. In addition, Dia.Pro's strong international focus, exporting over 80% of its revenues to more than 80 countries worldwide, will accelerate Clonit's ongoing internationalisation process, particularly in strategic markets such as the Middle East and South America.

Founded in 1987 and based in Abbiategrasso (MI), Clonit was a first mover in Italy in the field of molecular diagnostics, among the first companies in the country to introduce molecular biology techniques applied to human DNA for the identification of genetic mutations (genetic diseases) and infectious pathogens (viruses, bacteria, and parasites), supporting early infectious disease diagnosis. Today, Clonit is an excellence in the development, production, and distribution of innovative reagent kits for molecular tests mainly for infectious, genetic, and oncological diseases, with a distinctive market positioning thanks to its R&D capabilities and the strong know-how of its management team. Clonit's current product range includes high-quality molecular diagnostic kits for genetic and infectious diseases, along with new analytical targets in the fields of Genetics and Oncology.

Dia.Pro, founded in 1996 in Milan and based in Sesto San Giovanni, is an international excellence in immunological diagnostics for infectious diseases. The company boasts strong expertise in the development and production of in vitro, immunometric, and molecular diagnostic kits capable of identifying specific antibodies against infectious targets (antibodies to bacteria, viruses, and parasites) and against antigens. Thanks to its strong innovation-driven R&D division, the company has developed



robotic equipment and instruments capable of simultaneously analysing large quantities of biological samples and automating diagnostic processes.

The transaction represents the second add-on for Clonit, in which the Equita Smart Capital – ELTIF fund invested in July 2022, following the acquisition of Experteam, a company specialising in the diagnostics of genetically based diseases (infertility, degenerative diseases, and oncology) and in human, environmental, and food virology and microbiology.

Carlo Roccio, Chairman and Founder of Clonit, stated: *“This transaction represents the natural evolution of the growth path we have undertaken. The entry of Dia.Pro into the Group will bring new operational and commercial synergies, particularly in foreign markets, which are increasingly strategic for our development.”*

Dario Russo, CEO of Clonit, added: *“Combining our expertise with that of Dia.Pro means expanding our ability to innovate and offer advanced and reliable diagnostic solutions. We believe this new chapter will allow us to strengthen our positioning and compete more effectively in international markets and in a rapidly growing sector such as molecular diagnostics.”*

Marino Marchisio and Fiorenza Scozzesi, outgoing members of Dia.Pro’s Board of Directors, stated: *“Clonit’s vision and expertise are a great driver for Dia.Pro’s future development. This transaction will allow us to accelerate ongoing projects, consolidate our market presence, and seize new opportunities.”*

Edoardo Marchisio, CEO of Dia.Pro, commented: *“Clonit’s entry strengthens Dia.Pro’s structure and outlook, enabling the pooling of experiences, capabilities, and resources to provide even greater value to customers and partners. With this transaction, Dia.Pro reaffirms its commitment to continue growing with solidity, innovation, and a strategic openness toward key international markets and toward new high-profile collaborations.”*

Advisors:

In completing the transaction, **Clonit** was assisted by the law firm **DLA Piper** for all legal matters, by **Spada Partners** for the financial and tax due diligence, and by **Minerva Corporate Finance** as financial advisor.

Dia.Pro and its shareholders were supported by the law firm **Galbiati, Sacchi, Lamandini e Associati** for all legal aspects.

Close to Media – Communication Advisors: Adriana Liguori: adriana.liguori@closetomedia.it, Paolo Ferrario: paolo.ferrario@closetomedia.it, Elena Gioia: elena.gioia@closetomedia.it

FOR MORE INFORMATION:

Close to Media – Communication Advisors

Adriana Liguori: Mob. +39 345.1778974 – adriana.liguori@closetomedia.it

Paolo Ferrario: Mob. +39 337.1064754 – paolo.ferrario@closetomedia.it

Elena Gioia: Mob. +39 393. 812 8094 – elena.gioia@closetomedia.it